# Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)

> **NCT04773600** · PHASE3 · COMPLETED · sponsor: **Arcutis Biotherapeutics, Inc.** · enrollment: 683 (actual)

## Conditions studied

- Atopic Dermatitis Eczema

## Interventions

- **DRUG:** Roflumilast Cream
- **DRUG:** Vehicle cream

## Key facts

- **NCT ID:** NCT04773600
- **Lead sponsor:** Arcutis Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-24
- **Primary completion:** 2022-09-29
- **Final completion:** 2022-09-29
- **Target enrollment:** 683 (ACTUAL)
- **Last updated:** 2024-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04773600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04773600, "Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04773600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*